Tags

Type your tag names separated by a space and hit enter

Innovative parameters RET-Y, sTfR, and sTfR-F index in patients with microcytic, hypochromic anemia--their special value for hemoglobinopathies.
Lab Hematol. 2007; 13(2):63-8.LH

Abstract

The role of RET-Y (the mean value of the forward-scattered light histogram within the reticulocyte population), soluble transferrin receptor (sTfR), and the ratio of soluble transferrin receptor to log10 ferritin (sTfR-F index) in discriminating hemoglobinopathies remains unclear. For that purpose, a cohort of 141 patients with microcytic, hypochromic anemia, along with 58 healthy individuals, were evaluated in the present study. Patients were divided into 4 groups: A (beta-thalassemia trait, n=62), B (iron-deficiency anemia [IDA], n=41), C (alpha-thalassemia trait, n=10) and D (hemoglobin O-Arab trait, n=28). Whole blood count, RET-Y, ferritin, sTfR, and sTfR-F index were performed for each individual. Diagnostic efficiency was analyzed by receiver operating characteristic (ROC) curves. Youden index was used for the estimation of the cutoff points and the associated values for sensitivity and 1-specificity. Statistically significant differences were observed for RET-Y, sTfR-F, and sTfR-F index between patients and healthy individuals, except for sTfR-F index of group C; between groups A, D, and B for RET-Y; between groups C, D, and B for sTfR; and between groups A, C, D, and B for sTfR-F index. ROC curves were constructed considering IDA as a positive case and indicated a very good diagnostic ability for sTfR-F index (area under the ROC curve [AUCROC]=0.938, cutoff point >2.19) in differentiating IDA from hemoglobinopathies in the study population. When the beta-thalassemia trait was considered as a positive case, ROC curves demonstrated a very good diagnostic efficiency for RET-Y (AUCROC=0.894, cutoff point <1411.8 AU). In populations where hemoglobinopathies are frequent, the full blood count, including the new parameter RET-Y, and sTfR-F index provide an extra, simple, and accurate tool for diagnosis and genetic consulting.

Authors+Show Affiliations

Hematology Laboratory, General Hospital of Xanthi, Xanthi, Greece. vhrissan@civil.duth.grNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17573284

Citation

Agorasti, Athanasia, et al. "Innovative Parameters RET-Y, sTfR, and sTfR-F Index in Patients With Microcytic, Hypochromic Anemia--their Special Value for Hemoglobinopathies." Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology, vol. 13, no. 2, 2007, pp. 63-8.
Agorasti A, Trivellas T, Papadopoulos V, et al. Innovative parameters RET-Y, sTfR, and sTfR-F index in patients with microcytic, hypochromic anemia--their special value for hemoglobinopathies. Lab Hematol. 2007;13(2):63-8.
Agorasti, A., Trivellas, T., Papadopoulos, V., & Konstantinidou, D. (2007). Innovative parameters RET-Y, sTfR, and sTfR-F index in patients with microcytic, hypochromic anemia--their special value for hemoglobinopathies. Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology, 13(2), 63-8.
Agorasti A, et al. Innovative Parameters RET-Y, sTfR, and sTfR-F Index in Patients With Microcytic, Hypochromic Anemia--their Special Value for Hemoglobinopathies. Lab Hematol. 2007;13(2):63-8. PubMed PMID: 17573284.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Innovative parameters RET-Y, sTfR, and sTfR-F index in patients with microcytic, hypochromic anemia--their special value for hemoglobinopathies. AU - Agorasti,Athanasia, AU - Trivellas,Theodore, AU - Papadopoulos,Vassilios, AU - Konstantinidou,Despina, PY - 2007/6/19/pubmed PY - 2008/5/20/medline PY - 2007/6/19/entrez SP - 63 EP - 8 JF - Laboratory hematology : official publication of the International Society for Laboratory Hematology JO - Lab Hematol VL - 13 IS - 2 N2 - The role of RET-Y (the mean value of the forward-scattered light histogram within the reticulocyte population), soluble transferrin receptor (sTfR), and the ratio of soluble transferrin receptor to log10 ferritin (sTfR-F index) in discriminating hemoglobinopathies remains unclear. For that purpose, a cohort of 141 patients with microcytic, hypochromic anemia, along with 58 healthy individuals, were evaluated in the present study. Patients were divided into 4 groups: A (beta-thalassemia trait, n=62), B (iron-deficiency anemia [IDA], n=41), C (alpha-thalassemia trait, n=10) and D (hemoglobin O-Arab trait, n=28). Whole blood count, RET-Y, ferritin, sTfR, and sTfR-F index were performed for each individual. Diagnostic efficiency was analyzed by receiver operating characteristic (ROC) curves. Youden index was used for the estimation of the cutoff points and the associated values for sensitivity and 1-specificity. Statistically significant differences were observed for RET-Y, sTfR-F, and sTfR-F index between patients and healthy individuals, except for sTfR-F index of group C; between groups A, D, and B for RET-Y; between groups C, D, and B for sTfR; and between groups A, C, D, and B for sTfR-F index. ROC curves were constructed considering IDA as a positive case and indicated a very good diagnostic ability for sTfR-F index (area under the ROC curve [AUCROC]=0.938, cutoff point >2.19) in differentiating IDA from hemoglobinopathies in the study population. When the beta-thalassemia trait was considered as a positive case, ROC curves demonstrated a very good diagnostic efficiency for RET-Y (AUCROC=0.894, cutoff point <1411.8 AU). In populations where hemoglobinopathies are frequent, the full blood count, including the new parameter RET-Y, and sTfR-F index provide an extra, simple, and accurate tool for diagnosis and genetic consulting. SN - 1080-2924 UR - https://www.unboundmedicine.com/medline/citation/17573284/Innovative_parameters_RET_Y_sTfR_and_sTfR_F_index_in_patients_with_microcytic_hypochromic_anemia__their_special_value_for_hemoglobinopathies_ L2 - http://www.diseaseinfosearch.org/result/8872 DB - PRIME DP - Unbound Medicine ER -